December 26, 2006 -- Geron sometimes seems a house divided, with two quite different focuses to its clinical programs. One half of the company is facing the world of stem cells and the other half working in a more traditional program that is seeking to develop cancer therapies based on its knowledge of telomerase. We look at what the company has done to fill its diverse pipeline and at its prodigious fund-raising ability...
